Likewise, HER2 status might differ between primary and metastases tumors, and HER2 amplification has been shown to be ‘acquired’ in about 2–3% of metastatic breast cancers, following neo-adjuvant chemotherapy treatment [13]. Here, ERBB2 is linked to breast carcinoma.